- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, Belimumab 200 mg SC, Standard therapy
- Biological · Drug
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 839 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 68 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy
- Interventions
- Single Dose Group: Belimumab IV 240 mg, Single Dose Group: Belimumab SC 2 x 120 mg, Single Dose Group: Belimumab SC 1 x 240 mg, Single Dose Group: Belimumab SC 1 x 200 mg, Multiple Dose Group: Belimumab SC 2 x 120 mg weekly, Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
- Biological
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab 100 mg SC
- Drug
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Long Beach, California • Tampa, Florida + 7 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- SC belimumab 200 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more
- Conditions
- Multiple Sclerosis
- Interventions
- Belimumab, Short-course Ocrelizumab, Continued Ocrelizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab 200 mg/mL
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas